What is Forbion?
Headquartered in Naarden, the Netherlands, with satellite offices in Munich and Boston, Forbion has established itself as a leading venture capital entity since its independent inception in 2006, evolving from its origins as ABN AMRO Capital Life Sciences. The firm specializes in identifying, nurturing, and guiding biotechnology and biopharmaceutical companies through their developmental stages, from early-stage research to clinical advancement. Forbion's investment philosophy spans multiple fund strategies, with a pronounced emphasis on innovative therapeutics companies located in Europe and North America. Furthermore, its BioEconomy fund strategy extends its reach into sustainable solutions across food, agriculture, materials, and environmental technologies, showcasing a diversified approach to biotechnology investment. The firm also collaborates with BioGeneration Ventures on seed and early-stage ventures, demonstrating a commitment to fostering nascent innovation.
How much funding has Forbion raised?
Forbion has raised a total of $2.2B across 1 funding round:
Unspecified
$2.2B
Unspecified (2024): $2.2B, investors not publicly disclosed
What's next for Forbion?
The recent major strategic investment signals Forbion's intent to further solidify its position as a key player in the life sciences investment landscape. This capital will likely be deployed to enhance its existing fund strategies, potentially increasing the size and scope of its investments in therapeutics and BioEconomy ventures. The firm's focus on early-stage to clinical development companies, coupled with its geographical presence in Europe and North America, positions it to capitalize on emerging scientific breakthroughs. Forbion's commitment to responsible investment principles, as a signatory to the UN PRI, suggests a continued focus on sustainable and impactful ventures, aligning financial returns with broader societal benefits.
See full Forbion company page
